Cargando…

Need to Revisit Step Therapy for ARBs

Detalles Bibliográficos
Autores principales:	Ram, C. Venkata, Giles, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2007
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437880/ https://www.ncbi.nlm.nih.gov/pubmed/17672815 http://dx.doi.org/10.18553/jmcp.2007.13.6.528

Ejemplares similares

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy
por: Anderson, Shane D., et al.
Publicado: (2020)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Is there a difference in the effect between the ACEI and ARB on COVID‐19?
por: Chen, Jie, et al.
Publicado: (2020)

Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis
por: Ma, Linlin, et al.
Publicado: (2021)

ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking
por: Onweni, Chidinma L., et al.
Publicado: (2020)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

The place of ARBs in heart failure therapy: is aldosterone suppression the key?
por: Markan, Uma, et al.
Publicado: (2019)

ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?
por: Gong, Jin, et al.
Publicado: (2021)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)

Continue ACE inhibitors / ARB’S till further evidence in coronavirus disease 2019 (COVID-19)
por: Bansal, Sandeep, et al.
Publicado: (2020)

Repurposing ARBs as treatments for breast cancer
por: George, Amee J., et al.
Publicado: (2017)

The histological spectrum of ARB‐induced gastritis
por: Storozuk, Tanner, et al.
Publicado: (2022)

Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility
por: Zhao, Hong‐Jin, et al.
Publicado: (2020)

In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension
por: Yuan, Yuan, et al.
Publicado: (2020)

COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome
por: Hu, Jianhua, et al.
Publicado: (2020)

Administration of ACEI or ARB in chronic kidney disease patients with concomitant SARS-CoV-2 respiratory infection()
por: Mateo Gómez, Cristina, et al.
Publicado: (2021)

Ozone therapy in dentistry: revisited
por: Shamim, Thorakkal
Publicado: (2018)

Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care
por: Hurwitz, Jason T., et al.
Publicado: (2016)

A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer Germany
por: Hedenmalm, Karin, et al.
Publicado: (2023)

ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)

The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020)

Clinical and Genetic Findings of Autosomal Recessive Bestrophinopathy (ARB)
por: Habibi, Imen, et al.
Publicado: (2019)

Controversy regarding ACE inhibitors / ARBs in COVID-19
por: Soria Arcos, Federico, et al.
Publicado: (2020)

Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)

ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?
por: Kalyesubula, Robert, et al.
Publicado: (2014)

Leprosy: An Urgent Need to Step Up Surveillance
por: Dev, Sathish, et al.
Publicado: (2017)

Mortality in COVID-19 patients treated with ACEIs/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction
por: Alamer, Ahmad, et al.
Publicado: (2020)

Temporal variation, socioeconomic status, and out‐of‐hospital deaths as factors that influence mortality rates among hospitalized COVID‐19 patients receiving ACEIs/ARBs
por: Aftab, Owais M., et al.
Publicado: (2022)

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients
por: Dong, Ying, et al.
Publicado: (2022)

ARBs and risk of cancer: international and South African expert comment
Publicado: (2010)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

ASSOCIATION BETWEEN IN-HOSPITAL MORTALITY AND ACE/ARB INHIBITOR USAGE
por: Ruge, Max, et al.
Publicado: (2022)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

The Law of Attrition Revisited
por: Christensen, Helen, et al.
Publicado: (2006)

Ebola/Athens revisited.
por: Olson, P E, et al.
Publicado: (1998)

Facial hair revisited
por: Rehman, I.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ethn4jkbe69qolluav7qgi2550